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Introduction
The prognosis of patients diagnosed with Stage 4 prostate 
cancer is significantly impacted by the presence or absence 
of metastasis at diagnosis. Patients diagnosed with M1 
(metastatic) disease have worse survival compared to 
patients with stage 4 (S4) M0 disease. A large study 
reported that the most commonly encountered metastatic 
sites at diagnosis were bone (84%), distant lymph nodes 
(10.6%), liver (10.2%), and thorax (9.1%), while 18.4% 
of patients had more than one organ involved [1].
Two recent studies demonstrate that the site of metas-
tasis impacts survival rates. In a study that used Surveillance, 
Epidemiology, and End Results (SEER) data from 1991 
to 2009, patients with visceral metastasis had poor survival 
compared to patients with lymph node involvement only 
[2]. The same study estimated that the median overall 
survival for lymph node, bone, visceral, and bone plus 
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Abstract
The purpose of this study was to estimate the risk of developing skeletal- related 
events (SREs) based on site of metastasis at diagnosis and identify other predic-
tors of developing SREs among metastatic prostate cancer patients. We conducted 
a retrospective cohort study using linked SEER (Surveillance, Epidemiology, and 
End Results) and Medicare data and identified men over the age of 65 with 
incident metastatic prostate cancer diagnosed during 2005–2009. SREs included 
radiation (RAD), pathological fractures (PF), bone surgery (BS), and spinal cord 
compression (SCC). The association between site of metastasis at diagnosis and 
SRE was examined using a Cox proportional hazards model that accounts for 
death as a competing risk. Among 4404 men (median age: 79 years) with in-
cident metastatic prostate cancer, 44% experienced SREs at a median of 
9.6 months post diagnosis. Compared to bone metastasis only, our model showed 
that patients were significantly less likely to develop SREs if they had LN- only 
metastasis at diagnosis (Sub- Hazard Ratio [SHR] 0.56; 95% Confidence Interval 
[CI]: 0.43–0.72) or unknown site of metastasis (SHR: 0.79; CI: 0.64–0.97). Other 
predictors of reduced SRE risk were age 80+ years (SHR: 0.83; CI: 0.75–0.91), 
non- Hispanic Black (SHR: 0.77; CI: 0.65–0.90), or being diagnosed in year 2009 
(SHR: 0.85; CI: 0.72–0.99). Patients were significantly more likely to develop 
SREs if they received androgen deprivation therapy (SHR: 1.73; CI: 1.48–2.02) 
or had Gleason score 8–10 disease (SHR: 0.79; CI: 0.64–0.97). Compared to 
patients who present with bone metastasis only at diagnosis, patients presenting 
with other metastatic sites have similar risk of developing SREs, with the excep-
tion of those presenting with lymph node only metastasis who have a significantly 
reduced risk of SREs.
Cancer Medicine
Open Access
3301© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
SRE Risk by Site of Metastasis in PCaA. Hussain et al.
lymph node metastasis at diagnosis were 43, 24, 16, and 
14 months respectively. In a meta- analysis that pooled 
data from 5 phase III randomized clinical trials (RCTs), 
overall survival for castrate- resistant patients with lymph 
node only, liver ± bone, lung ± bone, bone ± lymph 
node, and other visceral metastasis (adrenal, brain) were 
27.0, 12.1, 16.5, 20.3, and 14.4 months [3].
Several population- based observational studies have 
shown that bone metastasis is associated with greater risk 
of skeletal complications, commonly referred to as skeletal- 
related events (SREs), including pathologic fracture (PF), 
spinal cord compression (SCC), bone palliative radio-
therapy (RAD), and bone surgery (BS), and contribute 
significantly to the burden of prostate cancer [4–6]. 
Zoledronic acid and, more recently denosumab, have been 
approved by the Food and Drug Administration since 
they delay onset of SREs in patients with bone metastasis 
[7, 8]. While it is known that patients with bone metas-
tasis at diagnosis are at high- risk of SREs, there is limited 
information on the impact of other sites of metastasis at 
presentation on the risk of SREs. The purpose of this 
study was to estimate the risk of developing an SRE among 
S4M1 patients presenting with various sites of metastasis 
at diagnosis and to identify patient factors that correlated 
with the risk of developing SRE.
Patients and Methods
Data source
We used linked Surveillance, Epidemiology, and End Results 
(SEER)- Medicare datasets to study the relationship between 
the site of metastasis at diagnosis and risk of developing 
an SRE during follow- up. The SEER- Medicare database 
links information from the National Cancer Institute’s 
SEER cancer registries and Medicare claims data from 
the Centers for Medicare and Medicaid Services. The SEER 
program collects cancer incidence and mortality rates from 
17 tumor registries across the U.S. covering 28% of the 
U.S. population [9]. Medicare claims provide information 
on health care services which are provided to and covered 
for Medicare beneficiaries from the time of Medicare 
eligibility until death.
Study cohort
This study used a retrospective cohort study design to 
identify patients with prostate cancer (SEER code 54). 
Information on the specific sites of distant metastasis in 
patients with M1 prostate cancer at diagnosis became 
available in the SEER registries of 2004 onwards, (using 
the derived American Joint Committee on Cancer stage 
grouping system, 6th edition) whereas such detailed 
staging information for M1 patients was not available 
prior to 2004 [10]. Thus, to obtain more accurate staging 
data this study included men aged 66 or older in SEER 
who were diagnosed with incident cases of M1 prostate 
cancer between 2005 and 2009. The 2004 cohort was 
excluded since it represented the first year of extracting 
the more ‘granular’ incident staging information from 
patient medical records, and hence was potentially more 
prone to discrepancies in documentation than during the 
subsequent years when more experience in extracting such 
data was gained. The follow- up period ended on December 
31, 2010, or earlier if patients enrolled in a health main-
tenance organization or dis- enrolled in Medicare Parts A 
and B or died during this time period. Patients were 
required to have continuous enrollment in Medicare Parts 
Figure 1. Cohort identification flow chart.
Men diagnosed with S4M1 PC between 2005 and 2009 
as their primary cancer 
(N = 8834)
66 years and older at diagnosis 
(n = 7273)
Continuously enrolled in Medicare Parts A/B in the 12 
months prior to month of diagnosis 
(n = 6623)
No cancer in the 5 years prior to prostate cancer 
diagnosis 
(n = 4412)
Known diagnosis month and year, alive at diagnosis, 
and had only one prostate cancer diagnosis 
(n = 4404)
Not enrolled in an HMO in the 12 months prior to 
month of diagnosis 
(n = 4740)
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A/B in the year prior to diagnosis in order to assess 
baseline Charlson Comorbidity Index (CCI) in the year 
prior to diagnosis. Patients were excluded from the final 
sample if they had history of cancer in the 5 years prior 
to diagnosis, if their diagnosis month or year was unknown, 
or if they received a postmortem prostate cancer diagnosis 
(Fig. 1).
Exposure, covariate, and endpoint definition
We used the ‘CS Mets at DX’ measure to identify the 
location of distant metastasis at diagnosis among the 2005 
to 2009 SEER cohort (http://web2.facs.org/cstage0204/
prostate/Prostate_hal.html). SREs were identified using 
Medicare claims, including the International Classification 
of Diseases 9th version Clinical Modification and the 
Healthcare Common Procedure Coding System that indi-
cated SCC, PF, BS, or RAD (Table 1), which was 
previously published [11]. Covariates used in the model 
included demographic variables (age at diagnosis, race/
ethnicity, Census location), clinical variables (CCI, per-
formance status proxies), prostate cancer variables (Gleason 
score at diagnosis), and treatment (androgen deprivation 
therapy receipt).
Statistical analysis
We examined the bivariate distributions between sociode-
mographic, clinical, and prostate cancer- specific factors 
as they relate to SRE status. Sub- Hazard Ratios (SHR) 
of experiencing a SRE were derived using the inverse 
probability of treatment weighted (IPTW) Cox proportional 
hazards model that accounted for deaths as a competing 
risk and adjusted for age, race/ethnicity, androgen dep-
rivation therapy receipt, comorbidities, performance status, 
Gleason score, and year of diagnosis. The IPTW was 
Table 1. ICD- 9 Codes and HCPCS codes used for identifying skeletal- related events (SRE) measures. 
Spinal cord compression
ICD- 9 3369, 7211, 7214, 72141, 72142, 72191, 7227, 72270, 72271 and 72273
HCPCS 63050, 63051, 22551, 22552,, 63064, 63066, 61343, s2348, 63075- 8, s2350, s2351, 63195, 63197, 
63199, 63001, 63003, 63005, 63011, 63015, 63016, 63017, 63170, 63012, 63045, 63046, 63047, 
63048, 63040, 63042, 63043, 63044, 63020, 63030, 63035, 22224, 22222, 22214, 22212, 22207, 
22206, 0274t, 0275t, c9729, 0202t, 22865, 0164t, 0094t, 0097t, 63057, 63056, 63055, 63081, 63082, 
63087, 63088, 63101, 63102, 63103, 63090, 63091, 63086 and 63085
Pathologic fractures
ICD- 9 7331, 73311, 73312, 73313, 73314, 73315, 73316, and 73319
HCPCS 8202, 8208, 8210, 8212, 73311, 8120, 8122, 8124, 73312, 8130, 8132, 8134, 8138, 73316, 8230, 
8232, 8238, 73313, 805, 806, 8200, 7331, 73310, 73319, 800, 807, 8080, 8082, 8084, 8088, 8100, 
8240, 8242, 80701, 80702, 80703, 80704, 80705, 80706, 80707, 80708, 80709, 80841, 80842, 
80843, and 80849
Trauma/nonroutine falls/accidents
ICD- 9 819, 828, 851, 852, 853, 854, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 8074, 9584, 80712, 
80713, 80714, 80715, 80716, 80717, 80718, 80719, E800- E848, E881, E882, E883, E884.0, E884.1, 
E884.5, E885.0, E885.1, E885.2, E885.3, E885.4, E886.0, E886.9, E888.0, and E888.1
Bone palliative radiotherapy
ICD- 9 9223, 9224, 9229, 9230, 9231, 9232, and 9239
HCPCS A9600, A9604, A9605, C9401, G0173, G0174, G0243, G0251, G0339, G0340, J3005, 0073T, 61793, 
61796, 61797, 61798, 63620, 63621,77371, 77372, 77373, 77401, 77402, 77403, 77404, 77406, 
77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416, 77418, 79005, 79101, 79200, 79300, 
79400, 79403, 79440, 79445, and 79999
Bone surgery
ICD- 9 7815, 7845, 7855, 7915, 7925, 7935, 7995, 7812, 7842, 7852, 7911, 7921, 7931, 7991, 7813, 7843, 
7853, 7912, 7922, 7932, 7992, 7817, 7847, 7857, 7916, 7926, 7936, 7996, 0353, 8102, 8103, 8104, 
8105, 8106, 8107, 8108, 7810, 7811, 7816, 7819, 7840, 7841, 7846, 7849, 7850, 7851, 7856, 7859, 
7910, 7919, 7920, 7929, 7930, 7939, 7990, and 7999
HCPCS 27187. 27235. 27236. 27244. 27245. 27248. 27269. 27495. 27506. 27507. 27509. 27511. 27513. 
27514. 23615. 23616. 23630. 24498. 24515, 24516. 24538, 24545, 24546, 24566, 24575, 24579, 
24582, 24586, 24587, 24635, 24665, 24666, 24685, 25490, 25491, 25492, 25515, 25525, 25526, 
25545, 25606, 25607, 25608, 25609, 27535, 27536, 27745, 27756, 27758, 27759, 27766, 27769, 
27784, 27792, 27826, 27827, 22325, 22326, 22327, 22328, 22520, 22521, 22522, 22532, 22533, 
22534, 22548, 22550, 22554, 22555, 22556, 22558, 22565, 22585, 22590, 22595, 22600, 22610, 
22612, 22614, 22615, 22625, 22630, 22632, 20982, 23490, 23515, 23585, 27215, 27216, 27217, 
27218, 27226, 27227, 27228, 27524, 27540, 22523, 22524, 22525, 22526, 22527, 25574, and 25575
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obtained in a two- step process. We first estimated the 
propensity score using a logistic regression modeling the 
probability of androgen deprivation therapy (ADT) receipt 
as the dependent variable. Then the inverse of the pro-
pensity score was used to weight the sample in a Cox 
proportional hazards model. IPTW was important since 
men who received ADT were expected to be systematically 
different from those who did not receive ADT, therefore 
adjusting for selection bias. Additionally, ADT was included 
in the Cox proportional hazards model since men who 
received ADT (even after mimicking randomization) were 
expected to have more SREs compared to men who did 
not receive ADT, thus adjusting for confounding bias due 
to ADT. Applying IPTW and Cox proportional hazards 
model is a form of doubly robust estimation that protects 
against mismodeling [12]. Since site of metastasis influ-
ences the hazard of death, a competing risks framework 
was preferred because site of metastasis may have no direct 
influence on the hazard of SRE but can be significantly 
associated with cumulative probability of SRE. A cumula-
tive incidence plot was generated for each site of metastasis 
based on the competing risks model. In our model, those 
who were lost to follow- up (HMO enrollment, Medicare 
Parts A/B disenrollment, or end of follow- up on December 
31, 2010) were censored. All statistical analyses were per-
formed using SAS software package (version 9.3, SAS 
Institute, Cary, NC) and Stata software package (version 
13, Stata, College Station, TX).
Results
Study sample characteristics
Among 4404 patients (mean follow up: 16.6 months) 
diagnosed with incident metastatic prostate cancer, 1135 
(25.8%) did not receive ADT, which is similar to what 
has been reported in prior SEER- Medicare studies [13, 
14]. Non- Hispanic Whites, and those with lower CCI and 
higher Gleason scores were more likely to experience SREs 
(P < 0.05). Table 2 shows the distribution of several of 
the available sociodemographic, clinical, and tumor- related 
characteristics in SEER, as categorized by SRE status at 
follow- up.
Association between metastatic site and SRE
The distribution of various sites of metastasis among the 
incident cases of M1 prostate cancer patients in the final 
sample is shown in Figure 2. Staging information was 
not available in 6% of patients in this cohort. The bone, 
with or without lymph node and/or ‘other’ (including 
visceral) sites of involvement represents the most common 
site of distant spread, with metastasis to bone only 
occurring in 59% of patients at initial presentation and 
to bone ± other sites in 68%. Twenty percent of the 
sample presented with metastasis to sites other than the 
bone or lymph node (designated as ‘other only’ sites which 
would include visceral organs), whereas only a minority 
of patients (4.7%) had lymph node only metastasis at 
initial presentation. Overall, 10% of men had metastasis 
Table 2. Demographic and clinical characteristics among M1 prostate 
cancer men diagnosed from 2005 to 2009, by skeletal- related events 
status (N = 4404).
Any skeletal- related event (N = 4404)
No (n = 2473) Yes (n = 1931) P value
N % N %
Age 0.06
66–70 416 17 356 18
71–75 457 18 390 20
76–80 499 20 402 21
80 + 1101 45 783 41
Race/Ethnicity 1824 74 1530 79 <0.01*
Non- Hispanic White
Non- Hispanic Black 368 15 200 10
Hispanic 160 6 106 6
Other 121 5 95 5
SEER census location
Northeast 476 19 391 20 0.16
South 487 20 329 17
North Central 353 14 282 15
West 1157 47 929 48
Married 1427 58 1139 59 0.39
Urban residence 2160 87 1732 90 0.01*
Charlson comorbidity index
0 1254 51 1059 55 <0.01*
1 462 18 396 21
2 239 10 161 8
3+ 241 10 175 9
Missing 277 11 140 7
Androgen deprivation 
therapy
1652 67 1617 84 <0.01*
Prediagnosis poor 
performance function
706 29 501 26 0.05
High PSA at baseline 2099 85 1664 86 0.23*
Poorly differentiated 
tumor
1457 59 1172 61 0.23
Gleason score
2–6 99 4 49 2 <0.01*
7 319 13 212 11
8–10 997 40 884 46
Not done/unknown 1058 43 786 41
Year of diagnosis
2005 482 19 466 24 <0.01*
2006 517 21 420 22
2007 460 19 363 19
2008 503 20 370 19
2009 511 21 312 16
*Significant at the P = 0.05 level.
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to two or more ‘organ’ sites (i.e., bone, lymph node and/
or ‘other’ sites) at diagnosis. On average, 44% of the 
final sample developed a SRE during follow- up. The pro-
portion of patients with the different sites of metastasis 
at initial presentation who developed a subsequent SRE 
during the follow- up period is shown in Figure 2; this 
ranged from 29% (lymph node metastasis only) to 52% 
(bone and lymph node metastasis). There was a statisti-
cally significant difference between SRE rates across the 
seven metastatic sites (P < 0.001).
In the Cox proportional hazards model that accounts 
for death as a competing risk, it is apparent that among 
the prostate cancer men with different sites of metastasis 
those with lymph node only involvement at diagnosis were 
significantly less likely to develop a SRE during follow- up 
compared to patients presenting with bone only metastasis 
at diagnosis (Sub- Hazard Ratio (SHR): 0.56; 95% Confidence 
Interval (CI): 0.43–0.72). Patients with ‘other’ site only, 
bone plus lymph node, bone plus ‘other’ site ± lymph 
node, and lymph node plus ‘other’ site were as likely as 
patients with bone metastasis only to develop SREs. Lastly, 
although the relevant extent of disease information was 
missing in the ‘unknown site of metastasis’ patient group, 
this group was also less likely to develop SREs (SHR: 0.79; 
95% CI: 0.64–0.97) compared to the bone metastasis only 
group (Table 3), perhaps in part reflecting that it may be 
more akin to the lymph node only population in terms 
of clinical behavior. Using the same model we have pro-
duced a cumulative incidence of SRE plot that shows the 
probability of developing SREs among various sites of 
metastasis. The probability of developing SREs within 3 years 
of diagnosis with Stage IV M1 prostate cancer among patients 
with various sites of metastasis were: lymph node only 
(29%), unknown site (36%), lymph node + other site (39%), 
other site (43%), bone only (45%), bone +other ± lymph 
node (47%), and bone + lymph node (50%).
Figure 2. Proportion of patients with the various metastatic sites at presentation and their skeletal- related events distribution.
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Other predictors of developing SREs
In the multivariable Cox proportional hazards model, 
patients were significantly less likely to develop SREs if 
they were over 80 years of age (SHR: 0.83; 95% CI: 
0.75–0.91), were of non- Hispanic Black ethnicity (SHR: 
0.77; 95% CI: 0.65–0.90), or were diagnosed in year 2009 
(SHR: 0.85; 95% CI: 0.72–0.99). On the other hand, 
patients were significantly more likely to develop SREs if 
they received androgen deprivation therapy (SHR: 1.73; 
95% CI: 1.48–2.02), or had a Gleason score of 8–10 (SHR: 
1.5; 95% CI: 1.13–1.98) (Table 3). Interestingly, the overall 
prevalence of SREs decreased over time from 2005 to 
2009 (P < 0.01).
SRE subtypes
Several statistically significant differences are noteworthy 
regarding the frequency of the different subtypes of SRE 
(i.e., RAD, BS, SCC, PF) with respect to certain covariates 
such as metastatic site, age, race, diagnosis year, and ADT 
receipt (Table 4). Radiation was statistically less likely 
among men who had lymph node only metastasis at 
diagnosis, were 80 years of age or older, were diagnosed 
with MI prostate cancer in year 2009 compared to the 
earlier years, or did not receive ADT for their prostate 
cancer. Bone surgery was statistically less likely among 
African American men, and those men who were diag-
nosed with prostate cancer in 2009. Pathologic fractures 
were less likely among African Americans, those less than 
age 80 or those who did not receive ADT. On the other 
hand, no significant differences with respect to spinal cord 
compression were found among the different covariates 
examined except for those M1 patients who did not receive 
ADT (this latter group had lower incidence of SCC) 
(Table 4).
Discussion
Metastasis to the bone is a common occurrence in men 
with advanced prostate cancer, and is associated with 
significant morbidity and mortality [15–18]. One approach 
to understanding the clinically relevant consequences of 
bone metastasis is to study what has been defined as 
SREs. This includes certain interventions such as RAD 
and BS, or certain clinical events such as PF and SCC, 
that can occur among patients with bone metastasis. 
Prospective clinical trials in patients with established bone 
metastasis have provided important information about 
SREs in cancer patients [15, 19, 20]. In an effort to better 
understand the occurrence patterns and impact of PF, 
SCC, RAD, and BS in a broader prostate cancer popula-
tion than what is typically defined in controlled clinical 
trials, we used the SEER- Medicare dataset to conduct the 
present analysis in a large cohort of men with stage IV 
M1 prostate cancer. This study took advantage of the 
fact that since 2004 onwards more detailed staging infor-
mation on M1 patients is being captured in SEER (M1a, 
M1b, M1c; i.e., sites of metastasis at diagnosis).
In contrast with most prior studies where SREs have 
been studied in men with bone metastasis [4, 5, 15, 19–21], 
our study is unique in that we evaluated patients with 
Table 3. Covariate adjusted SHR for skeletal related events among 
 patients diagnosed with M1 prostate cancer diagnosed from 2005 to 
2009.
Any SRE (N = 4404)
SHR 95% CI
Metastatic Site
Reference
BM Only
LN Only 0.56* (0.43, 0.72)
Other Only 0.94 (0.83, 1.06)
BM + LN 1.13 (0.92, 1.40)
BM + Other ± LN 1.06 (0.82, 1.37)
LN + Other 0.83 (0.54, 1.26)
Unknown 0.79* (0.64, 0.97)
Age
Reference
≤80
80+ 0.83* (0.75, 0.91)
Race/ethnicity
Reference
Non- hispanic white
Non- hispanic black 0.77* (0.65,0.90)
Hispanic 0.86 (0.70,1.06)
Other 0.90 (0.72,1.11)
Androgen deprivation therapy 1.73* (1.48,2.02)
Charlson comorbidity index
Reference
0
1 1.04 (0.92,1.17)
2 0.89 (0.74,1.07)
3+ 0.95 (0.80,1.14)
Missing 0.86 (0.71,1.03)
Prediagnosis poor  
performance function
1.18 (0.97,1.45)
Gleason score
Reference
2–6
7 1.19 (0.88,1.61)
8–10 1.50* (1.13,1.98)
Not done/unknown 1.66* (1.25,2.21)
Year of diagnosis
Reference
2005
2006 0.91 (0.79,1.04)
2007 0.91 (0.78,1.05)
2008 0.87 (0.75,1.00)
2009 0.85* (0.72,0.99)
SRE, skeletal related event; BM, bone metastasis; Other, Other metasta-
sis (excludes LN and bone); LN, Lymph node metastasis; SHR, sub- hazard 
ratios. *Significant at the P = 0.05 level. Poor performance function in-
dicates a claim for a walking aid or wheelchair use. We also controlled 
for SEER location. We also controlled for census location and marital 
status (not shown).
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different sites of metastasis, including those without bone 
metastasis at diagnosis, to determine the risk of develop-
ing SREs (as determined from claims data) among these 
different subgroups of prostate cancer patients. Using this 
approach, the present work documents that SREs can 
occur in all subcategories of M1 patients, although those 
with lymph node- only metastasis at presentation are sig-
nificantly less likely to experience SREs compared to the 
other subgroups (Fig. 2, Table 3). One possible reason 
why men with lymph node metastasis only at diagnosis 
have less SREs may be due to their lower likelihood of 
developing subsequent bone metastasis. However, since 
we were not able to identify bone metastasis after diag-
nosis, this cannot be confirmed from the present data.
In addition to the initial sites of metastasis, we found 
age, ethnicity, year of cancer diagnosis and ADT receipt, 
can also affect the risk of developing SREs among the 
M1 prostate cancer cohort (Table 4). Regarding age we 
found that the overall lower incidence of SREs in the 
80+ year old group is primarily due to the lower use of 
radiation amongst these patients compared to the 
66–80 year old age group. Amongst African Americans, 
lower risk of developing PF and lower use of BS (perhaps 
a consequence of lower PF) account for their overall lower 
incidence of SREs compared to the other ethnic groups. 
This observation is not inconsistent with the known lower 
risk of fractures in African Americans compared to 
European Americans, perhaps reflecting inherent differ-
ences in their respective skeletal physiology [22].
Another interesting observation relates to the use of 
ADT. ADT is the mainstay of treatment, and in fact 
represents the first line of treatment for M1 prostate cancer 
patients. Despite this, remarkably, 25.8% of the M1 cohort 
did not have claims for ADT receipt, a figure that is not 
inconsistent with what has been reported previously by 
others [10, 11]. Claims reflecting all four SRE subcom-
ponents are significantly less in the non- ADT group than 
in the corresponding ADT group (Table 4). The duration 
of follow- up for the non- ADT group is also considerably 
less than for the ADT group (4.9 vs. 19.5 months). Whether 
non- ADT patients receive lesser extent of medical services 
in general, as reflected by not getting a standard therapy 
(ADT) for their cancer in the first place and having sig-
nificantly less follow- up compared to ADT patients, and 
whether such factors in part contribute to lower SRE- 
related claims across all SRE subtypes among this group, 
is not altogether clear but will require further study.
This study has several limitations. First, the codes used 
to define SREs have not been validated and are subject 
to further research. A Danish study validated the ICD- 10 
coding of bone metastasis and SREs in prostate cancer 
and found that the sensitivity of ICD- 10 codes ranged 
from 44% to 55% and specificity ranged from 94% to 
100% [23]. Second, there is no billing code for SREs 
which makes it harder to directly identify SREs, especially 
radiation to bone. The inability to differentiate receipt of 
radiation to the prostate gland from radiation to the bone 
will result in overestimating the prevalence of radiation. 
However, by only assessing S4M1 patients, we believe that 
the majority of our sample receiving radiation is using 
it for bone palliation. Third, this study did not include 
younger patients diagnosed with incident S4M1 or elderly 
Figure 3. Inverse probability weighted and covariate adjusted cumulative incidence of experiencing an skeletal- related events according to metastatic 
site at diagnosis.
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patients who were initially diagnosed with nonmetastatic 
disease but developed bone metastasis  during follow- up.
In conclusion, this study documents risk of SREs among 
elderly metastatic prostate cancer patients, irrespective of 
whether patients had bone metastasis at diagnosis. Although 
we cannot determine from these data if such patients go 
on to develop bone metastasis over time, these results 
do provide important evidence for patients and oncolo-
gists concerning SRE risk among all metastatic patients. 
We also identified several factors such as age and race/
ethnicity that can modify the risk of SREs among meta-
static prostate cancer patients. The slight decrease in SREs 
over time is promising. Better prevention and management 
of SREs can help to minimize their impact on men with 
advanced prostate cancer.
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